A	O
Randomized	B:C2986910
Controlled	O
Open	O
-	I:C1709323
Label	I:C1709323
Pilot	I:C1709323
Study	I:C1709323
of	O
Simvastatin	O
Addition	O
to	O
Whole	O
-	I:C1520143
Brain	I:C1520143
Radiation	I:C1520143
Therapy	I:C1520143
in	O
Patients	O
With	O
Brain	O
Metastases	I:C0220650
.	O

A	O
Randomized	O
Controlled	B:C0681867
Open	O
-	I:C1709323
Label	I:C1709323
Pilot	I:C1709323
Study	I:C1709323
of	O
Simvastatin	O
Addition	O
to	O
Whole	O
-	I:C1520143
Brain	I:C1520143
Radiation	I:C1520143
Therapy	I:C1520143
in	O
Patients	O
With	O
Brain	O
Metastases	I:C0220650
.	O

A	O
Randomized	O
Controlled	O
Open	B:C1709323
-	I:C1709323
Label	I:C1709323
Pilot	I:C1709323
Study	I:C1709323
of	O
Simvastatin	O
Addition	O
to	O
Whole	O
-	I:C1520143
Brain	I:C1520143
Radiation	I:C1520143
Therapy	I:C1520143
in	O
Patients	O
With	O
Brain	O
Metastases	I:C0220650
.	O

A	O
Randomized	O
Controlled	O
Open	O
-	I:C1709323
Label	I:C1709323
Pilot	I:C1709323
Study	I:C1709323
of	O
Simvastatin	B:C0074554
Addition	O
to	O
Whole	O
-	I:C1520143
Brain	I:C1520143
Radiation	I:C1520143
Therapy	I:C1520143
in	O
Patients	O
With	O
Brain	O
Metastases	I:C0220650
.	O

A	O
Randomized	O
Controlled	O
Open	O
-	I:C1709323
Label	I:C1709323
Pilot	I:C1709323
Study	I:C1709323
of	O
Simvastatin	O
Addition	O
to	O
Whole	B:C1520143
-	I:C1520143
Brain	I:C1520143
Radiation	I:C1520143
Therapy	I:C1520143
in	O
Patients	O
With	O
Brain	O
Metastases	I:C0220650
.	O

A	O
Randomized	O
Controlled	O
Open	O
-	I:C1709323
Label	I:C1709323
Pilot	I:C1709323
Study	I:C1709323
of	O
Simvastatin	O
Addition	O
to	O
Whole	O
-	I:C1520143
Brain	I:C1520143
Radiation	I:C1520143
Therapy	I:C1520143
in	O
Patients	O
With	O
Brain	B:C0220650
Metastases	I:C0220650
.	O

Statins	B:C1254351
have	O
been	O
reported	O
to	O
have	O
a	O
potential	O
radiosensitizing	O
effect	I:C3179280
that	O
has	O
not	O
been	O
evaluated	O
in	O
clinical	O
trials	I:C0008976
.	O

Statins	O
have	O
been	O
reported	O
to	O
have	O
a	O
potential	O
radiosensitizing	B:C3179280
effect	I:C3179280
that	O
has	O
not	O
been	O
evaluated	O
in	O
clinical	O
trials	I:C0008976
.	O

Statins	O
have	O
been	O
reported	O
to	O
have	O
a	O
potential	O
radiosensitizing	O
effect	I:C3179280
that	O
has	O
not	O
been	O
evaluated	B:C0220825
in	O
clinical	O
trials	I:C0008976
.	O

Statins	O
have	O
been	O
reported	O
to	O
have	O
a	O
potential	O
radiosensitizing	O
effect	I:C3179280
that	O
has	O
not	O
been	O
evaluated	O
in	O
clinical	B:C0008976
trials	I:C0008976
.	O

The	O
aim	O
of	O
this	O
study	B:C0008972
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
simvastatin	O
in	O
addition	O
to	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
(	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
)	O
in	O
patients	O
with	O
brain	O
metastases	I:C0220650
(	O
brain	O
metastases	I:C0220650
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	B:C0220825
the	O
efficacy	O
and	O
safety	O
of	O
simvastatin	O
in	O
addition	O
to	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
(	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
)	O
in	O
patients	O
with	O
brain	O
metastases	I:C0220650
(	O
brain	O
metastases	I:C0220650
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
simvastatin	B:C0074554
in	O
addition	O
to	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
(	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
)	O
in	O
patients	O
with	O
brain	O
metastases	I:C0220650
(	O
brain	O
metastases	I:C0220650
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
simvastatin	O
in	O
addition	O
to	O
whole	B:C1520143
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
(	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
)	O
in	O
patients	O
with	O
brain	O
metastases	I:C0220650
(	O
brain	O
metastases	I:C0220650
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
simvastatin	O
in	O
addition	O
to	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
(	O
whole	B:C1520143
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
)	O
in	O
patients	O
with	O
brain	O
metastases	I:C0220650
(	O
brain	O
metastases	I:C0220650
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
simvastatin	O
in	O
addition	O
to	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
(	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
)	O
in	O
patients	O
with	O
brain	B:C0220650
metastases	I:C0220650
(	O
brain	O
metastases	I:C0220650
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
simvastatin	O
in	O
addition	O
to	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
(	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
)	O
in	O
patients	O
with	O
brain	O
metastases	I:C0220650
(	O
brain	B:C0220650
metastases	I:C0220650
)	O
.	O

A	O
prospective	B:C0033522
randomized	O
,	O
controlled	O
,	O
open	O
-	I:C1709323
label	I:C1709323
pilot	I:C1709323
study	I:C1709323
was	O
conducted	O
on	O
50	O
Egyptian	O
patients	O
with	O
brain	O
metastases	I:C0220650
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
30	O
-	I:C1520143
Gy	I:C1520143
WBRT	I:C1520143
(	O
control	O
group	O
:	O
25	O
patients	O
)	O
or	O
30	O
Gy	I:C1520143
WBRT	I:C1520143
+	O
simvastatin	O
80	O
mg	O
/	O
day	O
for	O
the	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
period	O
(	O
simvastatin	O
group	O
:	O
25	O
patients	O
)	O
.	O

A	O
prospective	O
randomized	B:C2986910
,	O
controlled	O
,	O
open	O
-	I:C1709323
label	I:C1709323
pilot	I:C1709323
study	I:C1709323
was	O
conducted	O
on	O
50	O
Egyptian	O
patients	O
with	O
brain	O
metastases	I:C0220650
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
30	O
-	I:C1520143
Gy	I:C1520143
WBRT	I:C1520143
(	O
control	O
group	O
:	O
25	O
patients	O
)	O
or	O
30	O
Gy	I:C1520143
WBRT	I:C1520143
+	O
simvastatin	O
80	O
mg	O
/	O
day	O
for	O
the	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
period	O
(	O
simvastatin	O
group	O
:	O
25	O
patients	O
)	O
.	O

A	O
prospective	O
randomized	O
,	O
controlled	B:C0681867
,	O
open	O
-	I:C1709323
label	I:C1709323
pilot	I:C1709323
study	I:C1709323
was	O
conducted	O
on	O
50	O
Egyptian	O
patients	O
with	O
brain	O
metastases	I:C0220650
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
30	O
-	I:C1520143
Gy	I:C1520143
WBRT	I:C1520143
(	O
control	O
group	O
:	O
25	O
patients	O
)	O
or	O
30	O
Gy	I:C1520143
WBRT	I:C1520143
+	O
simvastatin	O
80	O
mg	O
/	O
day	O
for	O
the	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
period	O
(	O
simvastatin	O
group	O
:	O
25	O
patients	O
)	O
.	O

A	O
prospective	O
randomized	O
,	O
controlled	O
,	O
open	B:C1709323
-	I:C1709323
label	I:C1709323
pilot	I:C1709323
study	I:C1709323
was	O
conducted	O
on	O
50	O
Egyptian	O
patients	O
with	O
brain	O
metastases	I:C0220650
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
30	O
-	I:C1520143
Gy	I:C1520143
WBRT	I:C1520143
(	O
control	O
group	O
:	O
25	O
patients	O
)	O
or	O
30	O
Gy	I:C1520143
WBRT	I:C1520143
+	O
simvastatin	O
80	O
mg	O
/	O
day	O
for	O
the	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
period	O
(	O
simvastatin	O
group	O
:	O
25	O
patients	O
)	O
.	O

A	O
prospective	O
randomized	O
,	O
controlled	O
,	O
open	O
-	I:C1709323
label	I:C1709323
pilot	I:C1709323
study	I:C1709323
was	O
conducted	O
on	O
50	O
Egyptian	B:C0337801
patients	O
with	O
brain	O
metastases	I:C0220650
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
30	O
-	I:C1520143
Gy	I:C1520143
WBRT	I:C1520143
(	O
control	O
group	O
:	O
25	O
patients	O
)	O
or	O
30	O
Gy	I:C1520143
WBRT	I:C1520143
+	O
simvastatin	O
80	O
mg	O
/	O
day	O
for	O
the	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
period	O
(	O
simvastatin	O
group	O
:	O
25	O
patients	O
)	O
.	O

A	O
prospective	O
randomized	O
,	O
controlled	O
,	O
open	O
-	I:C1709323
label	I:C1709323
pilot	I:C1709323
study	I:C1709323
was	O
conducted	O
on	O
50	O
Egyptian	O
patients	O
with	O
brain	B:C0220650
metastases	I:C0220650
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
30	O
-	I:C1520143
Gy	I:C1520143
WBRT	I:C1520143
(	O
control	O
group	O
:	O
25	O
patients	O
)	O
or	O
30	O
Gy	I:C1520143
WBRT	I:C1520143
+	O
simvastatin	O
80	O
mg	O
/	O
day	O
for	O
the	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
period	O
(	O
simvastatin	O
group	O
:	O
25	O
patients	O
)	O
.	O

A	O
prospective	O
randomized	O
,	O
controlled	O
,	O
open	O
-	I:C1709323
label	I:C1709323
pilot	I:C1709323
study	I:C1709323
was	O
conducted	O
on	O
50	O
Egyptian	O
patients	O
with	O
brain	O
metastases	I:C0220650
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
30	B:C1520143
-	I:C1520143
Gy	I:C1520143
WBRT	I:C1520143
(	O
control	O
group	O
:	O
25	O
patients	O
)	O
or	O
30	O
Gy	I:C1520143
WBRT	I:C1520143
+	O
simvastatin	O
80	O
mg	O
/	O
day	O
for	O
the	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
period	O
(	O
simvastatin	O
group	O
:	O
25	O
patients	O
)	O
.	O

A	O
prospective	O
randomized	O
,	O
controlled	O
,	O
open	O
-	I:C1709323
label	I:C1709323
pilot	I:C1709323
study	I:C1709323
was	O
conducted	O
on	O
50	O
Egyptian	O
patients	O
with	O
brain	O
metastases	I:C0220650
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
30	O
-	I:C1520143
Gy	I:C1520143
WBRT	I:C1520143
(	O
control	O
group	O
:	O
25	O
patients	O
)	O
or	O
30	B:C1520143
Gy	I:C1520143
WBRT	I:C1520143
+	O
simvastatin	O
80	O
mg	O
/	O
day	O
for	O
the	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
period	O
(	O
simvastatin	O
group	O
:	O
25	O
patients	O
)	O
.	O

A	O
prospective	O
randomized	O
,	O
controlled	O
,	O
open	O
-	I:C1709323
label	I:C1709323
pilot	I:C1709323
study	I:C1709323
was	O
conducted	O
on	O
50	O
Egyptian	O
patients	O
with	O
brain	O
metastases	I:C0220650
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
30	O
-	I:C1520143
Gy	I:C1520143
WBRT	I:C1520143
(	O
control	O
group	O
:	O
25	O
patients	O
)	O
or	O
30	O
Gy	I:C1520143
WBRT	I:C1520143
+	O
simvastatin	B:C0074554
80	O
mg	O
/	O
day	O
for	O
the	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
period	O
(	O
simvastatin	O
group	O
:	O
25	O
patients	O
)	O
.	O

A	O
prospective	O
randomized	O
,	O
controlled	O
,	O
open	O
-	I:C1709323
label	I:C1709323
pilot	I:C1709323
study	I:C1709323
was	O
conducted	O
on	O
50	O
Egyptian	O
patients	O
with	O
brain	O
metastases	I:C0220650
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
30	O
-	I:C1520143
Gy	I:C1520143
WBRT	I:C1520143
(	O
control	O
group	O
:	O
25	O
patients	O
)	O
or	O
30	O
Gy	I:C1520143
WBRT	I:C1520143
+	O
simvastatin	O
80	O
mg	O
/	O
day	O
for	O
the	O
whole	B:C1520143
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
period	O
(	O
simvastatin	O
group	O
:	O
25	O
patients	O
)	O
.	O

A	O
prospective	O
randomized	O
,	O
controlled	O
,	O
open	O
-	I:C1709323
label	I:C1709323
pilot	I:C1709323
study	I:C1709323
was	O
conducted	O
on	O
50	O
Egyptian	O
patients	O
with	O
brain	O
metastases	I:C0220650
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
30	O
-	I:C1520143
Gy	I:C1520143
WBRT	I:C1520143
(	O
control	O
group	O
:	O
25	O
patients	O
)	O
or	O
30	O
Gy	I:C1520143
WBRT	I:C1520143
+	O
simvastatin	O
80	O
mg	O
/	O
day	O
for	O
the	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
period	O
(	O
simvastatin	B:C0074554
group	O
:	O
25	O
patients	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
radiological	B:C0034533
response	O
at	O
4	O
weeks	O
after	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
.	O

The	O
primary	O
outcome	O
was	O
radiological	O
response	B:C4055223
at	O
4	O
weeks	O
after	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
.	O

The	O
primary	O
outcome	O
was	O
radiological	O
response	O
at	O
4	O
weeks	O
after	O
whole	B:C1520143
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
.	O

Secondary	O
outcomes	O
were	O
1	O
-	O
year	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
,	O
1	O
-	O
year	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQL	O
)	O
that	O
was	O
assessed	O
using	O
the	O
European	B:C0451149
Organization	I:C0451149
for	I:C0451149
the	I:C0451149
Research	I:C0451149
and	I:C0451149
Treatment	I:C0451149
of	I:C0451149
Cancer	I:C0451149
Quality	I:C0451149
of	I:C0451149
Life	I:C0451149
Questionnaire	I:C0451149
C30	I:C0451149
(	O
EORTC	O
QLQ	I:C0451149
-	I:C0451149
C30	I:C0451149
)	O
and	O
its	O
brain	O
module	I:C4054141
(	O
BN	O
-	I:C4054141
20	I:C4054141
)	O
,	O
at	O
baseline	O
,	O
after	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
,	O
and	O
4	O
weeks	O
after	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
.	O

Secondary	O
outcomes	O
were	O
1	O
-	O
year	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
,	O
1	O
-	O
year	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQL	O
)	O
that	O
was	O
assessed	O
using	O
the	O
European	O
Organization	I:C0451149
for	I:C0451149
the	I:C0451149
Research	I:C0451149
and	I:C0451149
Treatment	I:C0451149
of	I:C0451149
Cancer	I:C0451149
Quality	I:C0451149
of	I:C0451149
Life	I:C0451149
Questionnaire	I:C0451149
C30	I:C0451149
(	O
EORTC	B:C0451149
QLQ	I:C0451149
-	I:C0451149
C30	I:C0451149
)	O
and	O
its	O
brain	O
module	I:C4054141
(	O
BN	O
-	I:C4054141
20	I:C4054141
)	O
,	O
at	O
baseline	O
,	O
after	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
,	O
and	O
4	O
weeks	O
after	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
.	O

Secondary	O
outcomes	O
were	O
1	O
-	O
year	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
,	O
1	O
-	O
year	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQL	O
)	O
that	O
was	O
assessed	O
using	O
the	O
European	O
Organization	I:C0451149
for	I:C0451149
the	I:C0451149
Research	I:C0451149
and	I:C0451149
Treatment	I:C0451149
of	I:C0451149
Cancer	I:C0451149
Quality	I:C0451149
of	I:C0451149
Life	I:C0451149
Questionnaire	I:C0451149
C30	I:C0451149
(	O
EORTC	O
QLQ	I:C0451149
-	I:C0451149
C30	I:C0451149
)	O
and	O
its	O
brain	B:C4054141
module	I:C4054141
(	O
BN	O
-	I:C4054141
20	I:C4054141
)	O
,	O
at	O
baseline	O
,	O
after	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
,	O
and	O
4	O
weeks	O
after	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
.	O

Secondary	O
outcomes	O
were	O
1	O
-	O
year	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
,	O
1	O
-	O
year	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQL	O
)	O
that	O
was	O
assessed	O
using	O
the	O
European	O
Organization	I:C0451149
for	I:C0451149
the	I:C0451149
Research	I:C0451149
and	I:C0451149
Treatment	I:C0451149
of	I:C0451149
Cancer	I:C0451149
Quality	I:C0451149
of	I:C0451149
Life	I:C0451149
Questionnaire	I:C0451149
C30	I:C0451149
(	O
EORTC	O
QLQ	I:C0451149
-	I:C0451149
C30	I:C0451149
)	O
and	O
its	O
brain	O
module	I:C4054141
(	O
BN	B:C4054141
-	I:C4054141
20	I:C4054141
)	O
,	O
at	O
baseline	O
,	O
after	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
,	O
and	O
4	O
weeks	O
after	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
.	O

Secondary	O
outcomes	O
were	O
1	O
-	O
year	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
,	O
1	O
-	O
year	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQL	O
)	O
that	O
was	O
assessed	O
using	O
the	O
European	O
Organization	I:C0451149
for	I:C0451149
the	I:C0451149
Research	I:C0451149
and	I:C0451149
Treatment	I:C0451149
of	I:C0451149
Cancer	I:C0451149
Quality	I:C0451149
of	I:C0451149
Life	I:C0451149
Questionnaire	I:C0451149
C30	I:C0451149
(	O
EORTC	O
QLQ	I:C0451149
-	I:C0451149
C30	I:C0451149
)	O
and	O
its	O
brain	O
module	I:C4054141
(	O
BN	O
-	I:C4054141
20	I:C4054141
)	O
,	O
at	O
baseline	O
,	O
after	O
whole	B:C1520143
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
,	O
and	O
4	O
weeks	O
after	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
.	O

Secondary	O
outcomes	O
were	O
1	O
-	O
year	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
,	O
1	O
-	O
year	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQL	O
)	O
that	O
was	O
assessed	O
using	O
the	O
European	O
Organization	I:C0451149
for	I:C0451149
the	I:C0451149
Research	I:C0451149
and	I:C0451149
Treatment	I:C0451149
of	I:C0451149
Cancer	I:C0451149
Quality	I:C0451149
of	I:C0451149
Life	I:C0451149
Questionnaire	I:C0451149
C30	I:C0451149
(	O
EORTC	O
QLQ	I:C0451149
-	I:C0451149
C30	I:C0451149
)	O
and	O
its	O
brain	O
module	I:C4054141
(	O
BN	O
-	I:C4054141
20	I:C4054141
)	O
,	O
at	O
baseline	O
,	O
after	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
,	O
and	O
4	O
weeks	O
after	O
whole	B:C1520143
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
.	O

The	O
addition	O
of	O
simvastatin	B:C0074554
was	O
tolerated	O
.	O

Twenty	O
-	O
one	O
patients	O
were	O
not	O
evaluated	B:C0220825
for	O
radiological	O
response	O
because	O
of	O
death	O
(	O
n	O
=	O
16	O
)	O
,	O
noncompliance	O
to	O
follow	O
-	I:C1522577
up	I:C1522577
(	O
n	O
=	O
4	O
)	O
,	O
and	O
clinical	O
deterioration	O
(	O
n	O
=	O
1	O
)	O
.	O

Twenty	O
-	O
one	O
patients	O
were	O
not	O
evaluated	O
for	O
radiological	B:C0034533
response	O
because	O
of	O
death	O
(	O
n	O
=	O
16	O
)	O
,	O
noncompliance	O
to	O
follow	O
-	I:C1522577
up	I:C1522577
(	O
n	O
=	O
4	O
)	O
,	O
and	O
clinical	O
deterioration	O
(	O
n	O
=	O
1	O
)	O
.	O

Twenty	O
-	O
one	O
patients	O
were	O
not	O
evaluated	O
for	O
radiological	O
response	B:C4055223
because	O
of	O
death	O
(	O
n	O
=	O
16	O
)	O
,	O
noncompliance	O
to	O
follow	O
-	I:C1522577
up	I:C1522577
(	O
n	O
=	O
4	O
)	O
,	O
and	O
clinical	O
deterioration	O
(	O
n	O
=	O
1	O
)	O
.	O

Twenty	O
-	O
one	O
patients	O
were	O
not	O
evaluated	O
for	O
radiological	O
response	O
because	O
of	O
death	B:C0011065
(	O
n	O
=	O
16	O
)	O
,	O
noncompliance	O
to	O
follow	O
-	I:C1522577
up	I:C1522577
(	O
n	O
=	O
4	O
)	O
,	O
and	O
clinical	O
deterioration	O
(	O
n	O
=	O
1	O
)	O
.	O

Twenty	O
-	O
one	O
patients	O
were	O
not	O
evaluated	O
for	O
radiological	O
response	O
because	O
of	O
death	O
(	O
n	O
=	O
16	O
)	O
,	O
noncompliance	B:C0376405
to	O
follow	O
-	I:C1522577
up	I:C1522577
(	O
n	O
=	O
4	O
)	O
,	O
and	O
clinical	O
deterioration	O
(	O
n	O
=	O
1	O
)	O
.	O

Twenty	O
-	O
one	O
patients	O
were	O
not	O
evaluated	O
for	O
radiological	O
response	O
because	O
of	O
death	O
(	O
n	O
=	O
16	O
)	O
,	O
noncompliance	O
to	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
(	O
n	O
=	O
4	O
)	O
,	O
and	O
clinical	O
deterioration	O
(	O
n	O
=	O
1	O
)	O
.	O

Response	O
rates	O
were	O
60	O
%	O
and	O
78.6	O
%	O
(	O
p	O
=	O
0.427	O
)	O
,	O
1	O
-	O
year	O
PFS	O
rates	O
were	O
5.2	O
%	O
and	O
17.7	O
%	O
(	O
p	O
=	O
0.392	O
)	O
,	O
and	O
1	O
-	O
year	O
OS	O
rates	O
were	O
12	O
%	O
and	O
8	O
%	O
(	O
p	O
=	O
0.880	O
)	O
for	O
the	O
control	O
group	O
and	O
simvastatin	B:C0074554
group	O
,	O
respectively	O
.	O

The	O
addition	O
of	O
simvastatin	B:C0074554
80	O
mg	O
/	O
day	O
did	O
not	O
improve	O
the	O
clinical	O
outcomes	O
of	O
patients	O
with	O
brain	O
metastases	I:C0220650
receiving	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
.	O

The	O
addition	O
of	O
simvastatin	O
80	O
mg	O
/	O
day	O
did	O
not	O
improve	O
the	O
clinical	O
outcomes	O
of	O
patients	O
with	O
brain	B:C0220650
metastases	I:C0220650
receiving	O
whole	O
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
.	O

The	O
addition	O
of	O
simvastatin	O
80	O
mg	O
/	O
day	O
did	O
not	O
improve	O
the	O
clinical	O
outcomes	O
of	O
patients	O
with	O
brain	O
metastases	I:C0220650
receiving	O
whole	B:C1520143
-	I:C1520143
brain	I:C1520143
radiation	I:C1520143
therapy	I:C1520143
.	O

